Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2018 00:53 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA TO PROPOSE JACQUES THEURILLAT AS BOARD MEMBER

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Jacques Theurillat to be proposed...
March 27, 2018 00:55 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA CONCLUDES LICENSING AGREEMENT WITH ZERIA TO MARKET VELTASSA® IN JAPAN

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Vifor Pharma gives Zeria...
March 15, 2018 01:54 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA GROUP REPORTS STRONG 2017 RESULTS, EXCEEDING RAISED GUIDANCE

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} IN 2017 VIFOR PHARMA RECORDED A...
February 08, 2018 00:58 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA FERROPORTIN INHIBITOR ENTERS PHASE-I CLINICAL TRIAL

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} VIFOR PHARMA ANNOUNCED TODAY THAT...
January 04, 2018 00:58 ET | Source: Vifor Pharma Ltd.

AVACOPAN CONDITIONAL MARKETING AUTHORIZATION APPLICATION ACCEPTED FOR REGULATORY REVIEW BY EUROPEAN MEDICINES AGENCY

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Conditional marketing authorization...
January 04, 2018 00:53 ET | Source: Vifor Pharma Ltd.

VELTASSA® APPROVED FOR MARKETING IN SWITZERLAND FOR THE TREATMENT OF HYPERKALAEMIA

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Klicken Sie hier für Deutsch ...
November 23, 2017 00:59 ET | Source: Vifor Pharma Ltd.

THIRD GLOBAL IRON DEFICIENCY DAY TO RAISE AWARENESS OF THE SYMPTOMS OF IRON DEFICIENCY

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Iron Deficiency Day takes place...
September 27, 2017 00:56 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Additional Mircera® volume will...
August 08, 2017 00:55 ET | Source: Vifor Pharma Ltd.

VIFOR PHARMA REPORTS STRONG H1 2017 RESULTS AND RAISES GUIDANCE

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Strong financial performance in H1...
July 21, 2017 00:58 ET | Source: Vifor Pharma Ltd.

EUROPEAN COMMISSION APPROVES MARKETING AUTHORISATION FOR VELTASSA®

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Veltassa® approved for marketing...